Valneva, Serum Institute of India End Chikungunya Vaccine License Deal

MT Newswires · 2d ago
03:48 AM EST, 01/01/2026 (MT Newswires) -- Valneva (VLA.PA) and Serum Institute of India mutually agreed to end their license deal for the former's single-shot chikungunya vaccine. The move forms part of the French specialty vaccine company's plans to assume full commercialization rights and direct control over its supply chain, according to a Thursday release. Signed in December 2024, the license deal included a technology transfer for the vaccine's product manufacturing process, allowing the Serum Institute of India to manufacture and supply the vaccine in Asia.